Showing 20 of 29 recruiting trials for “follicular-lymphoma”
Nemolizumab to Treat Lichen Planopilaris, a Noncontrolled, Prospective, Pilot Study.
Ruxolitinib in Previously Treated Idiopathic Multicentric Castleman Disease
👨⚕️ Joshua Brandstadter, MD, PhD, MSc, University of Pennsylvania📍 1 site📅 Started Dec 2025View details ↗
Odronextamab in Low Tumor Volume Advanced FL
👨⚕️ Gottfried Von Keudell, MD, PhD, Beth Israel Deaconess Medical Center📍 1 site📅 Started Sep 2025View details ↗
Fixed-Duration Zanubrutinib, Bendamustine, and Obinutuzumab (ZBG) in Treatment-Naïve Advanced Stage Follicular Lymphoma
🏥 The First Affiliated Hospital with Nanjing Medical University📍 1 site📅 Started Jul 2025View details ↗
A Clinical Study of Allogeneic CD19/BCMA CAR-T Cells for the Treatment of R/R B-cell Malignant Tumors
Phase II Study of Pacritinib in Kaposi Sarcoma Herpesvirus (KSHV)-Associated Multicentric Castleman Disease and KSHV-Associated Inflammatory Cytokine Syndrome (KICS)
👨⚕️ Ramya M Ramaswami, M.D., National Cancer Institute (NCI)📍 1 site📅 Started Mar 2025View details ↗
RecruitingNCT06794268 ↗
A Study to Patients With Relapsed/Refractory Follicular Lymphoma Treated With Liso-cel (Lisocabtagene Maraleucel) in the Post Marketing Setting
Clinical Study of U01（ssCART-19） in Patients With B-Cell Lymphoma
Zanubrutinib Combined With G-CVP in Previously Untreated FL
🏥 Cancer Institute and Hospital, Chinese Academy of Medical Sciences📍 1 site📅 Started Jan 2025View details ↗
Universal CAR-T Cells (REVO-UWD-19) for Refractory and Relapsed B-Cell Tumors
👨⚕️ Pengcheng He, M.D. Ph.D., First Affiliated Hospital Xi'an Jiaotong University📍 1 site📅 Started Oct 2024View details ↗
A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients
👨⚕️ Chan Cheah, MBBS FRACP FRCPA DMSc, Sir Charles Gairdner Hospital (SCGH)📍 135 sites📅 Started Aug 2024View details ↗
Daratumumab for Relapsed/Refractory Primary Effusion Lymphoma, Plasmablastic Lymphoma, and Multicentric Castleman Disease
Study of Mosunetuzumab Plus Lenalidomide Compared to Anti-CD20 Anti-body + Chemotherapy in Follicular Lymphoma FLIPI2-5
RecruitingNCT06070961 ↗
Prospective Biological Study to Evaluate the Persistence of COVID-19 Vaccine and Other Vaccines'-Induced Immune Responses in Follicular Lymphoma Patients Undergoing Frontline Induction Immuno-chemotherapy and Anti-CD20 Maintenance
👨⚕️ Michele Merli, MD, U.O.C Ematologia, Ospedale di Circolo, Varese📍 14 sites📅 Started May 2024View details ↗
A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma
👨⚕️ Clinical Trial Management, Regeneron Pharmaceuticals📍 190 sites📅 Started Dec 2023View details ↗
Lenalidomide Combined With G-CHOP in the Treatment of Newly Diagnosed DLBCL With FL
👨⚕️ Bing Xu, PhD, The First Aiffiliated hosptical of xiamen University📍 1 site📅 Started Nov 2023View details ↗
Tazemetostat and Mosunetuzumab in Untreated Follicular Lymphoma
👨⚕️ Samuel Yamshon, M.D., Weill Medical College of Cornell University📍 1 site📅 Started Nov 2023View details ↗
RecruitingNCT05899621 ↗
A Real-world Study of Obinutuzumab-based Therapy for Previously Untreated FL
A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies
RecruitingNCT06720870 ↗
An Italian Multicenter Retrospective Observational Study to Assess Effectiveness and Safety of Siltuximab for Patients with Castleman's Disease Treated in Italy in a Real-life Context
👨⚕️ Pier Luigi Zinzani, MD, IRCCS Azienda Ospedaliero-Universitaria di Bologna📍 12 sites📅 Started Mar 2023View details ↗
Page 1 of 2Next →
Get alerts when new trials open
Create a free account to follow conditions and receive trial notifications.
Create free account →